Understand the source comparison
Follistatin-344 Results Timeline: Protocol Comparison
Different administration protocols produce measurably different timelines. The table below compares the three most common dosing schedules used in published research, showing how dose frequency and total exposure duration alter the kinetics of observable outco
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different administration protocols produce measurably different timelines. The table below compares the three most common dosing schedules used in published research, showing how dose frequency and total exposure duration alter the kinetics of observable outcomes.
- Low-Dose Continuous
- 100–200 mcg 3x/week
- Week 10–12
- Week 18–22
- 24 weeks minimum
- Slowest timeline but most sustainable. Lower peak myostatin suppression means gradual accretion without overshoot. Best for models intolerant of rapid composition shifts.
- Standard Protocol
- 300–500 mcg 2x/week
- Week 8–10
- Week 14–18
- 16–20 weeks
- Industry standard. Balances timeline compression with protocol manageability. Produces 15–22% hypertrophy in responsive models. Reconstitution every 7–10 days required.
- High-Dose Front-Load
- 500–1000 mcg daily (week 1–4), then 300 mcg 2x/week
- Week 6–8
- Week 12–16
- 16 weeks
- Fastest observable timeline but highest risk of receptor saturation and antibody formation. Front-loading accelerates satellite cell activation but doesn't meaningfully compress the proliferation/fusion timeline. Diminishing returns after week 4.
- The 'right' protocol depends entirely on research objectives. If the endpoint is mechanistic data on early satellite cell dynamics, a 6–8 week high-dose protocol captures that window efficiently. If the endpoint is quantifiable whole-muscle hypertrophy, nothing shorter than 12 weeks will produce statistically meaningful results, and 16–20 weeks is the evidence-based standard.